Status:
COMPLETED
Schizophrenia Trial of Aripiprazole
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Aripiprazole will show improved effectiveness over the standard of care treatment with one of three atypical antipsychotics (olanzapine, quetiapine and risperidone).
Eligibility Criteria
Inclusion
- Clinical diagnosis of schizophrenia
- Schizophrenia symptoms not optimally controlled or antipsychotic medication not well tolerated
Exclusion
- Diagnosis of schizoaffective disorder
- Patients treatment-resistant to antipsychotics
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT00237913
Start Date
July 1 2004
End Date
August 1 2005
Last Update
November 8 2013
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Vienna, Austria
2
Local Institution
Přerov, Czechia
3
Local Institution
Copenhagen, Denmark
4
Local Institution
Hørsholm, Denmark